Drugs / CYT002-NicQb
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00369616 | Dec 2003 → Mar 2005 | — | Cytos Biotechnology AG | Completed | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CYT002-NicQb | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00369616 ↗ |
| Modality | Vaccine | “A vaccine against nicotine was tested in a 6-month randomized, double blind phase II smoking cessation study” PMID 18575629 ↗ Jun 2008 |
| Route | Intramuscular | “229 subjects were randomized to receive five intramuscular injections of the nicotine vaccine” PMID 18575629 ↗ Jun 2008 |